KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Intangibles (2017 - 2025)

Novartis Ag's Intangibles history spans 8 years, with the latest figure at $29.4 billion for Q4 2025.

  • For Q4 2025, Intangibles rose 9.27% year-over-year to $29.4 billion; the TTM value through Dec 2025 reached $29.4 billion, up 9.27%, while the annual FY2025 figure was $29.4 billion, 9.27% up from the prior year.
  • Intangibles for Q4 2025 was $29.4 billion at Novartis Ag, up from $26.9 billion in the prior quarter.
  • Across five years, Intangibles topped out at $31.6 billion in Q4 2022 and bottomed at $26.9 billion in Q4 2023.
  • The 4-year median for Intangibles is $28.2 billion (2024), against an average of $28.7 billion.
  • The largest annual shift saw Intangibles fell 15.06% in 2023 before it grew 9.27% in 2025.
  • A 4-year view of Intangibles shows it stood at $31.6 billion in 2022, then fell by 15.06% to $26.9 billion in 2023, then grew by 0.13% to $26.9 billion in 2024, then rose by 9.27% to $29.4 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Intangibles are $29.4 billion (Q4 2025), $26.9 billion (Q4 2024), and $26.9 billion (Q4 2023).